Aytu BioPharma to Report Fiscal 2026 Full Year and Fourth Quarter Operational and Financial Results on September 22, 2026

Aytu BioPharma (AYTU) will report fiscal 2026 full year and fourth quarter operational and financial results after market close on Tuesday, September 22, 2026.

Rhea-AI Summary

Aytu BioPharma (AYTU) will report fiscal 2026 full year and fourth quarter operational and financial results after market close on Tuesday, September 22, 2026.

The company will host a conference call and webcast the same day at 4:30 p.m. Eastern time, including a question and answer session. U.S. participants can dial (888) 506-0062 and international participants can dial +1 (973) 528-0011, using access code 504506. A live and archived webcast will be available at the provided Webcaster link and in the Investors section of Aytu’s website under Events & Presentations. A teleconference replay will be accessible until October 6, 2026, using replay access code 54094 at the listed U.S. and international numbers.

Key Figures

Results reporting date: September 22, 2026

Results reporting date

September 22, 2026

Fiscal 2026 full-year and fourth-quarter results after market close

Key Terms

central nervous system diseases, extended-release tablets, boxed warning, major depressive disorder

4 terms

central nervous system diseases medical

"medicines for complex central nervous system diseases"

Disorders that affect the brain and spinal cord, including conditions such as Alzheimer’s, Parkinson’s, multiple sclerosis, epilepsy, stroke-related injury, and other diseases that disrupt nerve signaling and bodily control. They matter to investors because they drive demand for drugs, medical devices, diagnostics and long-term care, shape regulatory reviews and clinical trial risks, and can influence a company’s revenue prospects much like a large, persistent market need shapes sales for any long-term product.

extended-release tablets medical

"gepirone) extended-release tablets"

Tablets formulated to release their active drug ingredient gradually over an extended period after being swallowed, producing steadier blood levels than immediate‑release pills. Think of them like a timed sprinkler that waters slowly instead of a single quick burst. For investors, the formulation affects product differentiation, dosing convenience, regulatory review, manufacturing complexity, patent protection and market pricing—all factors that can influence a drug’s commercial value.

boxed warning regulatory

"including Boxed WARNING"

A boxed warning is the strongest safety alert a drug regulator places on a medication’s official label to highlight life‑threatening or very serious risks, similar to a bold red flag attached to a product. For investors, it matters because this warning can reduce sales, increase regulatory scrutiny, raise liability and monitoring costs, and change market perception of the drug’s future revenue and risk profile.

major depressive disorder medical

"for the treatment of major depressive disorder (MDD)"

A clinical condition characterized by persistent, severe low mood, loss of interest in daily activities, and reduced ability to function at work or home, lasting weeks or longer. It matters to investors because it drives demand for treatments and mental health services, affects workforce productivity and absenteeism, influences health-care and insurance costs, and shapes risks and opportunities for companies developing drugs, therapies or workplace programs—like a long-lasting storm that lowers economic output.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

DENVER, CO / ACCESS Newswire / September 16, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, will report its operational and financial results for its fiscal 2026 full year and fourth quarter, after the market close on Tuesday, September 22, 2026. The Company has scheduled a conference call and webcast that same day, Tuesday, September 22, 2026, at 4:30 p.m. Eastern time, to review the results followed by a question and answer session.

Conference Call Details

Date and Time: Tuesday, September 22, 2026, at 4:30 p.m. Eastern time.

Call-in Information: Interested parties can access the conference call by dialing (888) 506-0062 for United States callers or +1 (973) 528-0011 for international callers and using the participant access code 504506.

Webcast Information: The webcast will be accessible live and archived at https://www.webcaster5.com/Webcast/Page/2142/54094, and accessible on the Investors section of the Company's website at https://investors.aytubio.com/ under Events & Presentations.

Replay: A teleconference replay of the call will be available until October 6, 2026, at (877) 481-4010 for United States callers or +1 (919) 882-2331 for international callers and using replay access code 54094.

About Aytu BioPharma
Aytu is a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients. The Company's prescription products include EXXUA® (gepirone) extended-release tablets (see Full Prescribing Information, including Boxed WARNING) for the treatment of major depressive disorder (MDD), and treatments for attention deficit-hyperactivity disorder (ADHD). Aytu is committed to delivering the Company's medications through best-in-class patient access programs that help to enable optimal patient outcomes. For more information, please visit aytubio.com or follow us on LinkedIn.

Contacts for Investors
Ryan Selhorn, Chief Financial Officer
Aytu BioPharma, Inc.
rselhorn@aytubio.com

Robert Blum
Lytham Partners
aytu@lythampartners.com

SOURCE: Aytu BioPharma, Inc.

View the original press release on ACCESS Newswire

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How can investors join Aytu BioPharma’s September 22, 2026 earnings conference call?

Investors can join the call on Tuesday, September 22, 2026, at 4:30 p.m. Eastern time by dialing (888) 506-0062 in the United States or +1 (973) 528-0011 internationally and entering participant access code 504506. A live webcast will also be available at https://www.webcaster5.com/Webcast/Page/2142/54094 and via the Investors > Events & Presentations section of Aytu’s website.

How can the replay of Aytu BioPharma’s earnings call be accessed and until when?

The teleconference replay will be available until October 6, 2026, by dialing (877) 481-4010 for U.S. callers or +1 (919) 882-2331 for international callers and using replay access code 54094.